Safety of 300IR house dust mite sublingual tablet from pooled clinical trial and post-marketing data

Margitta Worm (1) , P Demoly (2, 3, 4) , Yoshitaka Okamoto (5) , Carmen Vidal (6) , Katia Daghildjian (7) , Kwok Yan (8) , Thomas Casale (9) , Karl-Christian Bergmann (1)

1 Charité - UniversitätsMedizin = Berlin University Medicine
2 CHU Montpellier = Montpellier University Hospital
3 IDESP - Institut Desbrest de santé publique
4 PREMEDICAL - Médecine de précision par intégration de données et inférence causale
5 Chiba University Hospital
6 Allergy Service [Santiago]
7 Stallergenes Greer
8 Royal Prince Alfred Hospital [Sydney, Australia]
9 USF - University of South Florida [Tampa]

The 300IR house dust mite (HDM) sublingual immunotherapy (SLIT) tablet is approved for treatment of HDM-induced allergic rhinitis (AR). To provide a comprehensive review of the 300IR HDM-SLIT tablet safety profile based on randomized controlled trial (RCT) pooled data and post-marketing (PM) pharmacovigilance data.

Mots clés: Allergic; Antigens; Asthma; Dermatophagoides; Dust mite allergy; Perennial; Rhinitis; Sublingual immunotherapy/adverse effects

Domaines: Sciences du Vivant [q-bio]

Margitta Worm, P Demoly, Yoshitaka Okamoto, Carmen Vidal, Katia Daghildjian, et al.. Safety of 300IR house dust mite sublingual tablet from pooled clinical trial and post-marketing data. World Allergy Organization Journal, 2024, 17 (7), pp.100924. ⟨10.1016/j.waojou.2024.100924⟩. ⟨hal-04921123⟩